title: Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France.
abstract: OBJECTIVE
  To define the role of a 10-Gy boost to the primary tumor in the conservative treatment of early infiltrating breast carcinoma treated by limited surgery and radiotherapy.
  
  
  METHODS
  Between 1986 and 1992, 1,024 women with early breast carcinoma (< or = 3 cm in diameter) were treated by local excision, axillary dissection, and conventional 50-Gy irradiation given in 20 fractions over 5 weeks and then randomly assigned to receive either no further treatment or a boost of 10 Gy by electrons to the tumor bed. The median follow-up time was 3.3 years as of September 1994. The occurrence of telangiectasia was reported, and the patients were asked to evaluate the cosmetic result.
  
  
  RESULTS
  At 5 years, 10 patients of 521 who had received the boost (Kaplan-Meier estimate of local relapse rate, 3.6%) and 20 of 503 who had received no further treatment (Kaplan-Meier estimate of local relapse rate, 4.5%) had developed a local recurrence (P = .044). After adjustment for the main prognostic variables, the relative risk was still significantly lower for the boost group (0.3; range, 0.12 to 0.95). The boost group had a higher rate of grade 1 and 2 telangiectasia (12.4% v 5.9%), but no difference was seen between the two treatment arms in the self-assessment score for the cosmetic result.
  
  
  CONCLUSIONS
  Delivery of a boost of 10 Gy to the tumor bed after 50 Gy to the whole breast following limited surgery significantly reduces the risk of early local recurrence, with no serious deterioration in the cosmetic result. Additional follow-up evaluation will be required to assess the long-term results.
authors.affiliation: Service de Radiothérapie-Oncologie des Hospices Civils de Lyon, CentreHospitalier Lyon Sud, Pierre Bénite, France.
authors.forename: P
authors.initials: P
authors.lastname: Romestaing
authors.forename: Y
authors.initials: Y
authors.lastname: Lehingue
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: R
authors.initials: R
authors.lastname: Coquard
authors.forename: X
authors.initials: X
authors.lastname: Montbarbon
authors.forename: J M
authors.initials: JM
authors.lastname: Ardiet
authors.forename: N
authors.initials: N
authors.lastname: Mamelle
authors.forename: J P
authors.initials: JP
authors.lastname: Gérard
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011446:Prospective Studies; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D013684:Telangiectasis / Q000453:epidemiology